BioNTech to buy FDA priority review voucher from Scholar Rock for $205 million
BioNTech has agreed to pay $205 million in cash for a US priority review voucher, intending to speed FDA review of a future late-stage oncology filing.
BioNTech SE announced on 10 November 2026 that it has agreed to acquire a US Food and Drug Administration (FDA) Priority Review Voucher from Scholar Rock. The price is $205 million in cash.
The company said it plans to use the voucher to accelerate FDA review of a future filing for a late-stage oncology asset. The summary of the announcement does not name the asset or give a filing date.
Closing of the transaction is subject to customary conditions, including clearance under the Hart-Scott-Rodino Act, the US antitrust pre-merger notification regime.
By way of context, a priority review voucher lets its holder obtain a priority review of a marketing application, which targets a shorter FDA review clock than standard review. Vouchers can be transferred, and sales between companies are a recognised way for sponsors to obtain one.
Why it matters
- Regulatory teams should note that BioNTech is signalling a future US filing for a late-stage oncology asset, though the asset and timing have not been disclosed.
- Market-access planners may need to consider the potential for a faster FDA review timeline for that asset once a filing is made.
- The deal is not yet complete: it depends on customary closing conditions, including Hart-Scott-Rodino clearance.
Company's press release (SEC filing): BioNTech SE ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
Helus Pharma, formerly Cybin, reports $150.9M six-month net loss as share compensation rises
IM Cannabis sells German arm to CEO-controlled Slil, refocusing on Israel
FDA sets 10 March 2027 goal date for Intellia's one-time hereditary angioedema gene-editing therapy
Quantum Biopharma narrows nine-month net loss to $17.3M as cash and digital assets rise
Candel delays prostate cancer BLA to mid-2027 as it refines assay with FDA
